RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

This study is testing a new cell therapy called RD13-02 — a type of engineered immune cell treatment that targets the CD7 protein — for people with a rare and aggressive blood cancer called NK/T cell lymphoma or leukemia that has come back or stopped responding to treatment. **You may be eligible if...** - You are 3–70 years old - You have been diagnosed with relapsed or refractory NK/T cell lymphoma that carries the CD7 protein marker - Your bone marrow contains at least 5% lymphoma cells - Your heart, kidney, liver, and lung function are adequate - Your expected survival is at least 3 months - You or your legal guardian can give informed consent **You may NOT be eligible if...** - You have a genetic syndrome associated with immune deficiency - Your heart is pumping at less than 50% efficiency - You have severe organ dysfunction - You are pregnant Talk to your doctor to see if this trial is right for you.